Oct 9 (Reuters) – Teva said on Friday it had received approval from the US Food and Drug Administration for its Weltruza drug for extended-release injectable suspension as the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.
Israel-based Teva, which is leading the development and commercialisation of the treatment under its partnership with France’s Medincell, said it expected to launch the product in the US in the coming weeks.
(Reporting by Lucie Barbier in Gdansk, editing by Milla Nissi-Prussak)
Comments